Amikacin

Suppresses premature stop mutation

Phase of research

FDA-approved for Cystic Fibrosis

How it helps

Anti-Infective,Restore CFTR Function

General information

Amikacin is a small-molecule aminoglycoside antibiotic effective against resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumanii. It was approved in the USA in 2018 and is sold under the brand name Arikayce®. It is used to treat Mycobacterium avium complex lung disease. In relation to cystic fibrosis, our AIM tool found the data that amikacin reduces Pseudomonas aeruginosa density, which leads to improved lung function. Amikacin can also suppress premature stop mutation (nonsense mutation) in the CFTR gene. 

Amikacin on PubChem
Amikacin on DrugBank
Amikacin on Wikipedia

Synonyms

amikacin sulfate

Marketed as

Dietary sources

N/A

Structure not available

C22H43N5O13

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
G542X
1 5.16
Link Tested on Impact factor Notes
Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. mice 5.16 More effective and less toxic than gentamicin.
General effect
3 0.00
Link Tested on Impact factor Notes
Amikacin for Inhalation (Transave) (Insmed TR02-106) humans N/A
Arikace compared to TOBI® in people with CF with chronic Pseudomonas aeruginosa infections (Insmed TR02-108) humans N/A Less effective than tobramycin.
Amikacin for Inhalation (Transave) (Insmed TR02-106) humans N/A

Does not treat

Mutation Number of sources Average impact factor